



Ref: FOIA Reference 2020/21-343

Royal Stoke University Hospital  
Data, Security and Protection  
Newcastle Road  
Stoke-on-Trent  
Staffordshire  
ST4 6QG

Date: 11<sup>th</sup> December 2020

Email [foi@uhnm.nhs.uk](mailto:foi@uhnm.nhs.uk)

Dear

I am writing in response to your email dated 17<sup>th</sup> November 2020 requesting information under the Freedom of Information Act (2000) regarding cancer.

I can neither confirm nor deny whether the information you have requested is held by the Trust in its entirety. This is because the information requested in questions 5 and 6 is not held centrally, but may be recorded in individual health records. In order to confirm whether this information is held we would therefore have to individually access all individual health records within the Trust and extract the information where it is present. We therefore estimate that complying with your request is exempt under section 12 of the FOI Act: *cost of compliance is excessive*. The section 12 exemption applies when it is estimated a request will take in excess of 18 hours to complete. We estimate that accessing and reviewing all individual health records and then extracting relevant information would take longer than the 18 hours allowed for.

In addition to the section 12 exemption the Trust is also applying section 14 (1) exemption: oppressive burden on the authority

Under section 16 of the FOI Act we are required to provide requestors with advice and assistance where possible. We would therefore like to advise you that if your request is shortened to just the questions that we are able to comply within the 18 hour time frame. In order to avoid delay to your response we have provided this below.

As of 1<sup>st</sup> November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

**Q1 Wilmington Healthcare is looking to understand the incidence and treatment of prostate and ovarian cancer in the UK. We would greatly appreciate if you could answer the following questions:**

**1. How many patients were diagnosed with prostate cancer over the last 3 months?  
Of these, how many patients were diagnosed with metastatic prostate cancer?**

A1 We are unable to provide some of the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section

40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers of as being <5.

This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.

Over the period 01/07/2020 to 30/09/2020 there were a total of 115 patients recorded with a diagnosis of prostate cancer at UHNM, breakdown as follows; 107 primary, 6 progression, <5 recurrence

**Q2 How many prostate cancer patients were treated over the last 3 months with?**

- a. Docetaxel
- b. Abiraterone
- c. Enzalutamide
- d. Cabazitaxel

A2 See below:

- a. Docetaxel = 17
- b. Abiraterone = 41
- c. Enzalutamide = 67
- d. Cabazitaxel = 10

**Q3 How many patients have been diagnosed with advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months?**

**If none, do you refer ovarian cancer patients to another Trust, if so which one?**

A3 Over the period 01/07/2020 to 30/09/2020 there were a total of 12 patients recorded with a FIGO Stages III or IV primary diagnosis of ovarian (epithelial ovarian, fallopian tube or primary peritoneal) at UHNM

**Q4 Of the ovarian cancer patients diagnosed over the last 3 months, how many have been treated with:**

- a. Paclitaxel in combination with a platinum-based compound
- b. Platinum-based therapy alone (cisplatin or carboplatin)
- c. Bevacizumab in combination with paclitaxel and carboplatin
- d. Olaparib
- e. Niraparib
- f. Rucaparib

A4 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5.

This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.

- a. Paclitaxel in combination with a platinum-based compound = <5

- b. Platinum-based therapy alone (cisplatin or carboplatin) = <5
- c. Bevacizumab in combination with paclitaxel and carboplatin = <5
- d. Olaparib = 0
- e. Niraparib = 0
- f. Rucaparib = 0

**Q5 Of the ovarian cancer patients diagnosed over the last 3 months, how many have been tested for the BRCA mutation? And of these, how many tested positive?**

A5 Section 12 and 14 exemptions as detailed above.

**Q6 Of the ovarian cancer patients who were positive for a BRCA mutation, how many patients received?**

- a. **Olaparib for 1st line maintenance**
- b. **Bevacizumab in combination with paclitaxel and carboplatin for 1st line maintenance**

A6 As answer 5

\*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

***UHM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.***

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.


Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via [www.ico.org.uk](http://www.ico.org.uk).

If following review of the responses I can be of any further assistance please contact my secretary on 01782 671612.

Yours,

A handwritten signature in black ink on a light-colored background. The signature reads "Jean Lehnert" in a cursive, slightly slanted script.

Jean Lehnert  
**Data, Security & Protection Manager**